Manganese Superoxide Dismutase as a Prognostic Factor in Glioblastoma
Author Information
Author(s): Ria F, Landriscina M, Remiddi F, Rosselli R, Iacoangeli M, Scerrati M, Pani G, Borrello S, Galeotti T
Primary Institution: Institute of General Pathology and Institute of Neurosurgery, Catholic University, Rome, Italy
Hypothesis
The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma.
Conclusion
Higher levels of manganese superoxide dismutase in glioblastomas are associated with shorter survival times.
Supporting Evidence
- Patients with high levels of manganese superoxide dismutase show a median survival time of 6.11 months.
- Patients with low manganese superoxide dismutase levels have a median survival time of 12.17 months.
- High manganese superoxide dismutase content is associated with cytoplasmic accumulation of p53 in astrocytomas.
Takeaway
This study found that patients with more manganese superoxide dismutase in their tumors tend to live shorter lives than those with less.
Methodology
The study compared the manganese superoxide dismutase levels in tumors of glioblastoma patients and analyzed their survival outcomes.
Participant Demographics
Patients affected by glioblastomas.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website